The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Open accessAbstract
The systematic translation of cancer genomic data into knowledge of tumour biology and therapeutic possibilities remains challenging. Such efforts should be greatly aided by robust preclinical model systems that reflect the genomic diversity of human cancers and for which detailed genetic and pharmacological annotation is available. Here we describe the Cancer Cell Line Encyclopedia (CCLE): a compilation of gene expression, chromosomal copy number and massively parallel sequencing data from 947 human cancer cell lines. When coupled with pharmacological profiles for 24 anticancer drugs across 479 of the cell lines, this collection allowed identification of genetic, lineage, and gene-expression-based predictors of drug sensitivity. In addition to known predictors, we found that plasma cell lineage correlated with sensitivity to IGF1 receptor inhibitors; AHR expression was associated with MEK inhibitor efficacy in NRAS-mutant lines; and SLFN11 expression predicted sensitivity to topoisomerase inhibitors. Together, our results indicate that large, annotated cell-line collections may help to enable preclinical stratification schemata for anticancer agents. The generation of genetic predictions of drug response in the preclinical setting and their incorporation into cancer clinical trial design could speed the emergence of 'personalized' therapeutic regimens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The CCLE dataset has previously been used to identify biomarkers for drug resistance and susceptibility (Barretina et al., 2012).”
From Efficient Parameter Estimation Enables the Prediction of Drug Response Using a Mechanistic Pan-Cancer Pathway Model (2018) · cites this paper as Barretina et al., 2012
In the citing paper
“JDQ443 antiproliferative activity was assessed by a high-throughput cell viability assay in a large panel of KRASG12C-mutated (N = 17) and non–G12C-mutated (N = 225) cell lines from the Cancer Cell Line Encyclopedia (29). JDQ443 demonstrated potent antiproliferative activity selectively toward the KRASG12C-mutated lines (Fig. 2A and B).”
In the citing paper
“However, large-scale drug sensitivity studies using the MEK and ERK inhibitors did not reveal the same degree of selectivity in KRAS mutant cells (69, 70) (Figure 4).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [69]
In the citing paper
“Large-scale efforts aimed at linking tumor genomic alterations with sensitivity to cytotoxic and targeted therapies have uncovered a wealth of pharmacogenomic interactions in NSCLC and other cancer types149–152.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [151]
In the citing paper
“interrogation of the expression data from the cancer cell line encyclopedia20 (CCLE) database revealed that classical SCLC cell lines have significantly reduced levels of EGFR mRNA compared with adenocarcinoma cell lines”
From RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer (2015) · cites this paper as [20]
In the citing paper
“Other expression datasets integrated into the latest version are the Cancer Cell Line Encyclopedia (16) and cell perturbation expression data from the Library of Integrated Network-Based Cellular Signatures (17).”
From TCRD and pharos 2021: mining the human proteome for disease biology (2021) · cites this paper as [16]
In the citing paper
“The Passport model name is accompanied by synonyms and most importantly unique identifiers utilized by established resources such as Research Resource Identifiers (RRID) (19), the Catalogue of Somatic Mutations in Cancer (COSMIC) (20) and CCLE (6) to aid data integration and alignment.”
From Cell Model Passports-a hub for clinical, genetic and functional datasets of preclinical cancer models (2019) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regularization and Variable Selection Via the Elastic Net
Zou, H., & Hastie, T. (2005) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.1467-9868.2005.00503.x · Cited by 20,957
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
Self-citationA collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
Neve, R. M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F. L., Fevr, T., Clark, L., Bayani, N., Coppé, J., Tong, F. K., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.008 · Cited by 3,224
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456
Systematic variation in gene expression patterns in human cancer cell lines
Ross, D. T., Scherf, U., Eisen, M. B., Perou, C. M., Rees, C., Spellman, P., Iyer, V., Jeffrey, S. S., Van de Rijn, M., Waltham, M., et al. (2000) · Nature Genetics · doi:10.1038/73432 · Cited by 2,088
Garraway, L. A., Widlund, H. R., Rubin, M. A., Getz, G., Berger, A. J., Ramaswamy, S., Beroukhim, R., Milner, D. A., Granter, S. R., Du, J., et al. (2005) · Nature · doi:10.1038/nature03664 · Cited by 1,548
Self-citationDiscovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
Tsai, J., Lee, J. T., Wang, W., Zhang, J., Cho, H., Mamo, S., Bremer, R., Gillette, S., Kong, J., Haass, N. K., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711741105 · Cited by 1,346
Self-citationBRAF mutation predicts sensitivity to MEK inhibition
Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G. A., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., et al. (2005) · Nature · doi:10.1038/nature04304 · Cited by 1,326
Self-citationAn Information-Intensive Approach to the Molecular Pharmacology of Cancer
Weinstein, J. N., Myers, T. G., O'Connor, P. M., Friend, S. H., Fornace, A. J., Kohn, K. W., Fojo, T., Bates, S. E., Rubinstein, L., Anderson, N. L., et al. (1997) · Science · doi:10.1126/science.275.5298.343 · Cited by 1,183
High-throughput oncogene mutation profiling in human cancer
Thomas, R. K., Baker, A. C., Debiasi, R. M., Winckler, W., LaFramboise, T., Lin, W. M., Wang, M., Feng, W., Zander, T., MacConaill, L. E., et al. (2007) · Nature Genetics · doi:10.1038/ng1975 · Cited by 978
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 701–800 of 1,107
Schick, S., Rendeiro, A. F., Runggatscher, K., Ringler, A., Boidol, B., Hinkel, M., Májek, P., Vulliard, L., Penz, T., Parapatics, K., et al. (2019) · Nature Genetics · doi:10.1038/s41588-019-0477-9 · Cited by 147
Bioinformatics Approaches for Anti-cancer Drug Discovery
Li, K., Du, Y., Li, L., & Wei, D. (2019) · Current Drug Targets · doi:10.2174/1389450120666190923162203 · Cited by 145
Mitochondrial DNA stress signalling protects the nuclear genome
Wu, Z., Oeck, S., West, A. P., Mangalhara, K. C., Sainz, A. G., Newman, L. E., Zhang, X.-O., Wu, L., Yan, Q., Bosenberg, M., et al. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0150-8 · Cited by 147
Pan, J., Meyers, R. M., Michel, B. C., Mashtalir, N., Sizemore, A. E., Wells, J. N., Cassel, S. H., Vázquez, F., Weir, B. A., Hahn, W. C., et al. (2018) · Cell Systems · doi:10.1016/j.cels.2018.04.011 · Cited by 134
Kategaya, L., Perumal, S. K., Hager, J. H., & Belmont, L. D. (2019) · iScience · doi:10.1016/j.isci.2019.02.006 · Cited by 144
Harmonizome 3.0: integrated knowledge about genes and proteins from diverse multi-omics resources
Diamant, I., Clarke, D. J. B., Evangelista, J. E., Lingam, N., & Ma’ayan, A. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae1080 · Cited by 176
Fröhlich, F., Kessler, T., Weindl, D., Shadrin, A., Schmiester, L., Hache, H., Muradyan, A., Schütte, M., Lim, J.-H., Heinig, M., et al. (2018) · Cell Systems · doi:10.1016/j.cels.2018.10.013 · Cited by 143
Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer
McMillan, E. A., Ryu, M.-J., Diep, C. H., Mendiratta, S., Clemenceau, J. R., Vaden, R. M., Kim, J.-H., Motoyaji, T., Covington, K. R., Peyton, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.028 · Cited by 141
Ortmayr, K., Dubuis, S., & Zampieri, M. (2019) · Nature Communications · doi:10.1038/s41467-019-09695-9 · Cited by 142
Glaser, A. P., Fantini, D., Wang, Y., Yu, Y., Rimar, K. J., Podojil, J. R., Miller, S. D., & Meeks, J. J. (2017) · Oncotarget · doi:10.18632/oncotarget.23344 · Cited by 143
Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers
Ferretti, S., Hamon, J., de Kanter, R., Scheufler, C., Andraos, R., Barbé, S., Bechter, E., Blank, J., Bordas, V., Dammassa, E., et al. (2024) · Nature · doi:10.1038/s41586-024-07350-y · Cited by 152
LncMAP: Pan-cancer atlas of long noncoding RNA-mediated transcriptional network perturbations
Li, Y., Li, X., Wang, Z., Pan, T., Sahni, N., Jin, X., Wang, G., Li, J., Zheng, X., Zhang, Y., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx1311 · Cited by 139
Weiss, A., Lorthiois, E., Barys, L., Beyer, K. S., Bomio-Confaglia, C., Burks, H., Chen, X., Cui, X., de Kanter, R., Dharmarajan, L., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0158 · Cited by 150
Calling in SYK: SYK's dual role as a tumor promoter and tumor suppressor in cancer
Krisenko, M. O., & Geahlen, R. L. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2014.10.022 · Cited by 142
canSAR: an updated cancer research and drug discovery knowledgebase
Tym, J. E., Mitsopoulos, C., Coker, E. A., Razaz, P., Schierz, A. C., Antolín, A. A., & Al‐Lazikani, B. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv1030 · Cited by 136
Modeling cancer drug response through drug-specific informative genes
Parca, L., Pepe, G., Pietrosanto, M., Galvan, G., Galli, L., Palmeri, A., Sciandrone, M., Ferrè, F., Ausiello, G., & Helmer‐Citterich, M. (2019) · Scientific Reports · doi:10.1038/s41598-019-50720-0 · Cited by 147
KRAS-G12C Mutation Is Associated with Poor Outcome in Surgically Resected Lung Adenocarcinoma
Nadal, E., Chen, G., Prensner, J. R., Shiratsuchi, H., Sam, C., Zhao, L., Kalemkerian, G. P., Brenner, D. E., Lin, J., Reddy, R. M., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000305 · Cited by 147
Busch, B., Bley, N., Müller, S., Glaß, M., Misiak, D., Lederer, M., Vetter, M., Strauß, H., Thomssen, C., & Hüttelmaier, S. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw099 · Cited by 139
Translational applications of adult stem cell-derived organoids
Drost, J., & Clevers, H. C. (2017) · Development · doi:10.1242/dev.140566 · Cited by 144
Wang, L., Gong, Y., Saci, A., Szabó, P. M., Martini, A., Necchi, A., Siefker-Radtke, A. O., Pal, S. K., Plimack, E. R., Sfakianos, J. P., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.06.025 · Cited by 141
Self-citationPatient-derived organoid (PDO) platforms to facilitate clinical decision making
Liu, L., Yu, L., Li, Z., Li, W., & Huang, W. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-020-02677-2 · Cited by 145
Deep learning methods for drug response prediction in cancer: Predominant and emerging trends
Partin, A., Brettin, T. S., Zhu, Y., Narykov, O., Clyde, A., Overbeek, J., & Stevens, R. L. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1086097 · Cited by 155
Lysosomal control of senescence and inflammation through cholesterol partitioning
Roh, K., Noh, J., Kim, Y., Jang, Y., Kim, J., Choi, H., Lee, Y., Ji, M., Kang, D., Kim, M.-S., et al. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00747-5 · Cited by 149
Geeleher, P., Zhang, Z., Wang, F., Gruener, R. F., Nath, A., Morrison, G., Bhutra, S., Grossman, R. L., & Huang, R. S. (2017) · Genome Research · doi:10.1101/gr.221077.117 · Cited by 142
Popova, T., Manié, E., Boeva, V., Battistella, A., Goundiam, O., Smith, N. K., Mueller, C. R., Raynal, V., Mariani, O., Sastre-Garau, X., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2128 · Cited by 130
Exploration of databases and methods supporting drug repurposing: a comprehensive survey
Tanoli, Z., Seemab, U., Scherer, A., Wennerberg, K., Tang, J., & Vähä-Koskela, M. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa003 · Cited by 131
PI3K Pathway Dependencies in Endometrioid Endometrial Cancer Cell Lines
Weigelt, B., Warne, P. H., Lambros, M. B. K., Reis-Filho, J. S., & Downward, J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3815 · Cited by 138
Nodwell, M. B., Yang, H., Čolović, M., Yuan, Z., Merkens, H., Martin, R. E., Bénard, F., Schaffer, P. C., & Britton, R. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.6b11533 · Cited by 143
Rhabdomyosarcoma, Ewing Sarcoma, and Other Round Cell Sarcomas
Pappo, A. S., & Dirksen, U. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.7402 · Cited by 138
Identification of MOSPD2, a novel scaffold for endoplasmic reticulum membrane contact sites
Mattia, T. D., Wilhelm, L. P., Ikhlef, S., Wendling, C., Spehner, D., Nominé, Y., Giordano, F., Mathelin, C., Drin, G., Tomasetto, C., et al. (2018) · EMBO Reports · doi:10.15252/embr.201745453 · Cited by 143
Wu, C., Lyu, J., Yang, E. J., Liu, Y., Zhang, B., & Shim, J. S. (2018) · Nature Communications · doi:10.1038/s41467-018-05694-4 · Cited by 136
Xiang, Z., Li, J., Song, S., Wang, J., Cai, W., Hu, W., Ji, J., Zhu, Z., Zang, L., Yan, R., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1318-5 · Cited by 138
Liu, C., Dong, W. G., Xiang, J., Ren, F., Huang, L., Lang, J., Tian, G., Li, Y., & Yang, J. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.07.003 · Cited by 138
Interpretable systems biomarkers predict response to immune-checkpoint inhibitors
Lapuente-Santana, Ó., van Genderen, M. N. G., Hilbers, P. A. J., Finotello, F., & Eduati, F. (2021) · Patterns · doi:10.1016/j.patter.2021.100293 · Cited by 142
Bianchi, A., Silva, I. D. C., Deshpande, N., Singh, S. P., Mehra, S., Garrido, V. T., Guo, X., Nivelo, L. A., Kolonias, D. S., Saigh, S. J., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1046 · Cited by 138
Artificial Intelligence in Pharmaceutical Sciences
Lu, M., Yin, J., Zhu, Q., Lin, G., Mou, M., Liu, F., Pan, Z., You, N., Lian, X., Li, F., et al. (2023) · Engineering · doi:10.1016/j.eng.2023.01.014 · Cited by 145
INX-315, a Selective CDK2 Inhibitor, Induces Cell Cycle Arrest and Senescence in Solid Tumors
Dietrich, C. A., Trub, A. G., Ahn, A., Taylor, M., Ambani, K., Chan, K. T., Lu, K., Mahendra, C. A., Blyth, C., Coulson, R. S., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0954 · Cited by 142
The lncRNA CASC15 regulates SOX4 expression in RUNX1-rearranged acute leukemia
Fernando, T. R., Contreras, J. R., Zampini, M., Rodriguez-Malave, N. I., Alberti, M. O., Anguiano, J., Tran, T. M., Palanichamy, J. K., Gajeton, J., Ung, N. M., et al. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0692-x · Cited by 141
Lind, A. P., & Anderson, P. C. (2019) · PLoS ONE · doi:10.1371/journal.pone.0219774 · Cited by 141
The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells
Kurimchak, A. M., Herrera-Montávez, C., Montserrat-Sangrà, S., Araiza-Olivera, D., Hu, J., Neumann-Domer, R., Kuruvilla, M., Bellacosa, A., Testa, J. R., Jin, J., et al. (2022) · Science Signaling · doi:10.1126/scisignal.abn2707 · Cited by 136
DNA damage-induced cell death relies on SLFN11-dependent cleavage of distinct type II tRNAs
Li, M., Kao, E., Malone, D., Gao, X., Wang, J. Y. J., & David, M. (2018) · Nature Structural & Molecular Biology · doi:10.1038/s41594-018-0142-5 · Cited by 136
RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer
Serra, V., Eichhorn, P. J. A., García-García, C., Ibrahim, Y. H., Prudkin, L., Sánchez, G., Rodríguez, O., Antón, P., Parra, J.-L., Marlow, S., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66343 · Cited by 140
Self-citationBalko, J. M., Schwarz, L. J., Luo, N., Estrada, M. V., Giltnane, J. M., Dávila‐González, D., Wang, K., Sanchez, V. M., Dean, P. T., Combs, S. E., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad3001 · Cited by 139
Si, X., Zang, R., Zhang, E., Liu, Y., Xiao Hua, S. H. I., Zhang, E., Shao, L., Li, A., Yang, N., Han, X., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13263 · Cited by 136
Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies
Herold, N., Rudd, S. G., Ljungblad, L. M., Sanjiv, K., Myrberg, I. H., Paulin, C. B. J., Heshmati, Y., Hagenkort, A., Kutzner, J., Page, B. D. G., et al. (2017) · Nature Medicine · doi:10.1038/nm.4265 · Cited by 135
Mathematical modeling and computational prediction of cancer drug resistance
Sun, X., & Hu, B. X. (2017) · Briefings in Bioinformatics · doi:10.1093/bib/bbx065 · Cited by 142
Johnson, A. M., Bullock, B., Neuwelt, A. J., Poczobutt, J. M., Kaspar, R. E., Li, H. Y., Kwak, J., Hopp, K., Weiser-Evans, M. C. M., Heasley, L. E., et al. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.1900778 · Cited by 134
Raho, S., Capobianco, L., Malivindi, R., Vozza, A., Piazzolla, C., Leonardis, F. D., Gorgoglione, R., Scarcia, P., Pezzuto, F., Agrimi, G., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-00315-1 · Cited by 138
Polyamine-mediated ferroptosis amplification acts as a targetable vulnerability in cancer
Bi, G., Liang, J., Bian, Y., Shan, G., Huang, Y., Lu, T., Zhang, H., Jin, X. Y., Chen, Z., Zhao, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46776-w · Cited by 154
Identification of Druggable Cancer Driver Genes Amplified across TCGA Datasets
Chen, Y., McGee, J., Chen, X., Doman, T. N., Gong, X., Zhang, Y., Hamm, N., Ma, X., Higgs, R. E., Bhagwat, S. V., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098293 · Cited by 138
Global regulation of alternative splicing by adenosine deaminase acting on RNA (ADAR)
Solomon, O., Oren, S., Safran, M., Deshet‐Unger, N., Akiva, P., Jacob‐Hirsch, J., Cesarkas, K., Kabesa, R., Amariglio, N., Unger, R., et al. (2013) · RNA · doi:10.1261/rna.038042.112 · Cited by 138
Parsels, L. A., Karnak, D. M., Parsels, J. D., Zhang, Q., Vélez-Padilla, J., Reichert, Z. R., Wahl, D. R., Maybaum, J., O’Connor, M. J., Lawrence, T. S., et al. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0455 · Cited by 135
Direct Phosphorylation and Stabilization of MYC by Aurora B Kinase Promote T-cell Leukemogenesis
Jiang, J., Wang, J., Yue, M., Cai, X., Wang, T., Wu, C., Su, H., Wang, Y., Han, M., Zhang, Y., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.01.001 · Cited by 135
p53 regulates a non-apoptotic death induced by ROS
Montero, J., Dutta, C., van Bodegom, D., Weinstock, D. M., & Letai, A. G. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.52 · Cited by 138
Targeting the Adaptability of Heterogeneous Aneuploids
Chen, G., Mulla, W. A., Kucharavy, A., Tsai, H.-J., RUBINSTEIN, B. Y., Conkright, J. J., McCroskey, S., Bradford, W. D., Weems, L., Haug, J. S., et al. (2015) · Cell · doi:10.1016/j.cell.2015.01.026 · Cited by 135
Cescon, D. W., Haibe‐Kains, B., & Mak, T. W. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424869112 · Cited by 134
Multiomics Evaluation of Gastrointestinal and Other Clinical Characteristics of COVID-19
Du, M., Cai, G., Chen, F., Christiani, D. C., Zhang, Z., & Wang, M. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.03.045 · Cited by 138
USP30 sets a trigger threshold for PINK1–PARKIN amplification of mitochondrial ubiquitylation
Rusilowicz-Jones, E. V., Jardine, J., Kallinos, A., Pinto-Fernández, A., Guenther, F., Giurrandino, M., Barone, F. G., McCarron, K. R., Burke, C. J., Murad, A., et al. (2020) · Life Science Alliance · doi:10.26508/lsa.202000768 · Cited by 135
ARID1A suppresses R-loop-mediated STING-type I interferon pathway activation of anti-tumor immunity
Maxwell, M. B., Hom, M. S., Yi, J., Li, S., Rivera, S. A., Yu, J., Burns, M. J., McRae, H. M., Stevenson, B. T., Coakley, K. E., et al. (2024) · Cell · doi:10.1016/j.cell.2024.04.025 · Cited by 147
Self-citationLLY-507, a Cell-active, Potent, and Selective Inhibitor of Protein-lysine Methyltransferase SMYD2
Nguyen, H., Allali‐Hassani, A., Antonysamy, S., Chang, S. S., Chen, L. H., Curtis, C., Emtage, S., Li, F., Gheyi, T., Li, F., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.626861 · Cited by 132
Kim, J., Fox, C., Peng, S., Pusung, M., Pectasides, E., Matthée, E., Hong, Y. S., Do, I., Jang, J., Thorner, A. R., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75200 · Cited by 133
Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer
Le, X., Antony, R., Razavi, P., Treacy, D. J., Luo, F., Ghandi, M., Castel, P., Scaltriti, M., Baselga, J. M., & Garraway, L. A. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0305 · Cited by 135
Self-citationVenetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression
Lochmann, T. L., Floros, K. V., Naseri, M., Powell, K. M., Cook, W., March, R. J., Stein, G. T., Greninger, P., Maves, Y. K., Saunders, L. R., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1606 · Cited by 134
A Multi-center Study on the Reproducibility of Drug-Response Assays in Mammalian Cell Lines
Niepel, M., Hafner, M., Mills, C. E., Subramanian, K., Williams, E. H., Chung, M., Gaudio, B., Barrette, A. M., Stern, A. D., Hu, B., et al. (2019) · Cell Systems · doi:10.1016/j.cels.2019.06.005 · Cited by 133
Self-citationPandey, K., Park, N., Park, K., Hur, J., Cho, Y. B., Kang, M., An, H., Kim, S., Hwang, S., & Moon, Y. W. (2020) · Cancers · doi:10.3390/cancers12123566 · Cited by 136
Self-citationCollateral lethality: a new therapeutic strategy in oncology
Muller, F. L., Aquilanti, E. A., & DePinho, R. A. (2015) · Trends in Cancer · doi:10.1016/j.trecan.2015.10.002 · Cited by 132
Discovery of Drug Synergies in Gastric Cancer Cells Predicted by Logical Modeling
Flobak, Å., Baudot, A., Rémy, É., Thommesen, L., Thieffry, D., Kuiper, M. T. R., & Lægreid, A. (2015) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1004426 · Cited by 134
Pereira, P. M. R., Sharma, S. K., Carter, L. M., Edwards, K. J., Pourat, J., Ragupathi, A., Janjigian, Y. Y., Durack, J. C., & Lewis, J. S. (2018) · Nature Communications · doi:10.1038/s41467-018-07608-w · Cited by 132
Rhie, S. K., Perez, A. A., Lay, F. D., Schreiner, S., Shi, J., Polin, J., & Farnham, P. (2019) · Nature Communications · doi:10.1038/s41467-019-12079-8 · Cited by 130
A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma
Amaravadi, R. K., Schilder, R. J., Martin, L. P., Levin, M. J., Graham, M. A., Weng, D. E., & Adjei, A. A. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0475 · Cited by 131
Kudinov, A. E., Deneka, A. Y., Nikonova, A. S., Beck, T. N., Ahn, Y., Liu, X., Martinez, C. F., Schultz, F. A., Reynolds, S., Yang, D., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1513616113 · Cited by 135
Harnessing synthetic lethality to predict the response to cancer treatment
Lee, J. S., Das, A., Jerby‐Arnon, L., Arafeh, R., Auslander, N., Davidson, M. A., McGarry, L., James, D. T., Amzallag, A., Park, S. G., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04647-1 · Cited by 122
Kim, H., Kim, E., Lee, I., Bae, B., Park, M., & Nam, H. (2020) · Biotechnology and Bioprocess Engineering · doi:10.1007/s12257-020-0049-y · Cited by 146
Cotto, K. C., Feng, Y.-Y., Ramu, A., Richters, M. M., Freshour, S. L., Skidmore, Z. L., Xia, H., McMichael, J. F., Kunisaki, J., Campbell, K. M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37266-6 · Cited by 179
Harane, S. E., Zidi, B., Harane, N. E., Krause, K., Matthes, T., & Preynat‐Seauve, O. (2023) · Cells · doi:10.3390/cells12071001 · Cited by 135
Faber, A. C., Farago, A. F., Costa, C., Dastur, A., Gomez-Caraballo, M., Robbins, R., Wagner, B. L., Rideout, W. M., Jakubik, C. T., Ham, J., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1411848112 · Cited by 127
Ham, J., Costa, C., Sano, R., Lochmann, T. L., Sennott, E. M., Patel, N. U., Dastur, A., Gomez‐Caraballo, M., Krytska, K., Hata, A. N., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.01.002 · Cited by 135
LGR5-Targeted Antibody–Drug Conjugate Eradicates Gastrointestinal Tumors and Prevents Recurrence
Gong, X., Azhdarinia, A., Ghosh, S. C., Xiong, W., An, Z., Liu, Q., & Carmon, K. S. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0114 · Cited by 130
The role of wild type RAS isoforms in cancer
Zhou, B., Der, C. J., & Cox, A. D. (2016) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2016.07.012 · Cited by 130
ZEB1‐mediated melanoma cell plasticity enhances resistance to MAPK inhibitors
Richard, G., Dalle, S., Monet, M., Plaschka, M., Boespflug, A. M., Pommier, R. M., de la Fouchardière, A., Perier‐Muzet, M., Depaepe, L., Barnault, R., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201505971 · Cited by 140
Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function ERF Mutations
Huang, F. W., Mosquera, J. M., Garofalo, A., Oh, C., Baco, M. B., Amin‐Mansour, A., Rabasha, B., Bahl, S., Mullane, S. A., Robinson, B. D., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0960 · Cited by 136
Self-citationInsel, P. A., Sriram, K., Wiley, S. Z., Wilderman, A. S., Katakia, T., McCann, T., Yokouchi, H., Zhang, L., Corriden, R., Liu, D., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00431 · Cited by 129
Generating Single Cell–Derived Knockout Clones in Mammalian Cells with CRISPR/Cas9
Giuliano, C. J., Lin, A., Girish, V., & Sheltzer, J. M. (2019) · Current Protocols in Molecular Biology · doi:10.1002/cpmb.100 · Cited by 130
Oshi, M., Takahashi, H., Tokumaru, Y., Yan, L., Rashid, O. M., Nagahashi, M., Matsuyama, R., Endo, I., & Takabe, K. (2020) · Cells · doi:10.3390/cells9071643 · Cited by 130
Beyondcell: targeting cancer therapeutic heterogeneity in single-cell RNA-seq data
Torre, C. F., Jiménez‐Santos, M. J., García‐Martín, S., Carretero-Puche, C., García-Jimeno, L., Ivanchuk, V., Domenico, T. D., Goméz-López, G., & Al‐Shahrour, F. (2021) · Genome Medicine · doi:10.1186/s13073-021-01001-x · Cited by 131
Drug toxicity assessment: cell proliferation versus cell death
Sazonova, E. V., Chesnokov, M. S., Zhivotovsky, B., & Kopeina, G. S. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01207-x · Cited by 142
A rapid and sensitive assay for DNA–protein covalent complexes in living cells
Kiianitsa, K., & Maizels, N. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt171 · Cited by 128
He, Y., Zhu, Q., Chen, M., Huang, Q., Wang, W., Li, Q., Huang, Y., & Di, W. J. (2016) · Oncotarget · doi:10.18632/oncotarget.12223 · Cited by 136
Ramesh, A., Arumugam, P., Priyadharsini, J. V., & Srinivasan, C. (2020) · PubMed Central · Cited by 128
CancerDR: Cancer Drug Resistance Database
Kumar, R., Chaudhary, K., Gupta, S., Singh, H., Kumar, S., Gautam, A., Kapoor, P., & Raghava, G. P. S. (2013) · Scientific Reports · doi:10.1038/srep01445 · Cited by 129
Self-citationImproved large-scale prediction of growth inhibition patterns using the NCI60 cancer cell line panel
Cortés‐Ciriano, I., van Westen, G. J. P., Bouvier, G., Nilges, M., Overington, J. P., Bender, A., & Malliavin, T. E. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btv529 · Cited by 123
MERAV: a tool for comparing gene expression across human tissues and cell types
Shaul, Y. D., Yuan, B., Thiru, P., Nutter-Upham, A., McCallum, S., Lanzkron, C., Bell, G. W., & Sabatini, D. M. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv1337 · Cited by 127
Mao, Y., Feng, Q., Zheng, P., Yang, L., Liu, T., Xu, Y., Zhu, D., Chang, W., Ji, M., Ren, L., et al. (2018) · Cancer Management and Research · doi:10.2147/cmar.s171855 · Cited by 128
Effect Sizes of Somatic Mutations in Cancer
Cannataro, V. L., Gaffney, S. G., & Townsend, J. P. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy168 · Cited by 128
Solan, M. E., Koperski, C. P., Senthilkumar, S., & Lavado, R. (2023) · Environmental Research · doi:10.1016/j.envres.2023.115424 · Cited by 126
Mouse hospital and co-clinical trial project—from bench to bedside
Clohessy, J. G., & Pandolfi, P. P. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.62 · Cited by 130
Epigenetic plasticity: A central regulator of epithelial-to-mesenchymal transition in cancer
Bedi, U., Mishra, V. K., Wasilewski, D., Scheel, C., & Johnsen, S. A. (2014) · Oncotarget · doi:10.18632/oncotarget.1875 · Cited by 131
Chemokines, cytokines and exosomes help tumors to shape inflammatory microenvironment
Атретханы, К.-С. Н., Drutskaya, M. S., Nedospasov, S. A., Grivennikov, S. I., & Kuprash, D. V. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.09.011 · Cited by 131
Zhang, X., Choi, P. S., Francis, J. M., Gao, G. F., Campbell, J. D., Ramachandran, A., Mitsuishi, Y., Ha, G., Shih, J., Vázquez, F., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0532 · Cited by 126
Self-citationA global transcriptional network connecting noncoding mutations to changes in tumor gene expression
Zhang, W., Bojorquez-Gomez, A., Velez, D. O., Xu, G., Sanchez, K. S., Shen, J. P., Chen, K., Licon, K., Melton, C. A., Olson, K. M., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0091-2 · Cited by 126
Metadata
- Authors
- Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., Reddy, A., Liu, M., Murray, L., Berger, M. F., Monahan, J. E., Morais, P., Meltzer, J., Korejwa, A., Jané-Valbuena, J., Mapa, F. A., Thibault, J., Bric-Furlong, E., Raman, P., Shipway, A., Engels, I. H., Cheng, J., Yu, G. K., Yu, J., Aspesi, P., de Silva, M., Jagtap, K., Jones, M. D., Wang, L., Hatton, C., Palescandolo, E., Gupta, S., Mahan, S., Sougnez, C., Onofrio, R. C., Liefeld, T., MacConaill, L., Winckler, W., Reich, M., Li, N., Mesirov, J. P., Gabriel, S. B., Getz, G., Ardlie, K., Chan, V., Myer, V. E., Weber, B. L., Porter, J., Warmuth, M., Finan, P., Harris, J. L., Meyerson, M., Golub, T. R., Morrissey, M. P., Sellers, W. R., Schlegel, R., & Garraway, L. A.
- Affiliations
- Broad Institute (US)
- Genomics Institute of the Novartis Research Foundation (US)
- Harvard University (US)
- Corresponding author
- Schlegel, Robert
- Garraway, Levi A.
- ORCID
- Barretina, Jordi
- Stransky, Nicolas
- Venkatesan, Kavitha
- Wilson, Christopher J.
- Lehár, Joseph
- Kryukov, Gregory V.
- Sonkin, Dmitriy
- Reddy, Anupama
- Liu, Manway
- Murray, Lauren
- Berger, Michael F.
- Monahan, John E.
- Mapa, Felipa A.
- Raman, Pichai
- Yu, Guoying K.
- Yu, Jianjun
- Aspesi, Peter
- Jones, Michael D.
- Wang, Li
- Gupta, Supriya
- Liefeld, Ted
- MacConaill, Laura
- Winckler, Wendy
- Reich, Michael
- Li, Nanxin
- Mesirov, Jill P.
- Gabriel, Stacey B.
- Getz, Gad
- Ardlie, Kristin
- Chan, Vivien
- Myer, Vic E.
- Weber, Barbara L.
- Meyerson, Matthew
- Golub, Todd R.
- Sellers, William R.
- Garraway, Levi A.
- Venue
- Nature
- Published
- 2012-03-28
- Volume
- 483
- Issue
- 7391
- Pages
- 603-607
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3320027
- OpenAlex
- W2043398720
- Cited by
- 7,950
- References
- 28
- Citations by year
- 2026: 361 · 2025: 501 · 2024: 617 · 2023: 719 · 2022: 723 · 2021: 839 · 2020: 682 · 2019: 687 · 2018: 628 · 2017: 500 · 2016: 516 · 2015: 436 · 2014: 348 · 2013: 283 · 2012: 103
- FWCI
- 124.24
- Type
- journal article
- Language
- en
- Update notices
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institutes of Health (DP2OD002750)
- National Human Genome Research Institute (U54HG003067)
- National Cancer Institute (R33CA155554, R33CA126674)
- National Institute of General Medical Sciences (R01GM074024)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- Cancer Cell Line Encyclopedia, anticancer drug sensitivity, drug resistance, cancer cell lines, Ewing sarcoma, PARP inhibitors, SLFN11, topoisomerase inhibitors, MEK inhibitors, NRAS mutation, aryl hydrocarbon receptor, gene expression profiles, chromosomal copy number, predictive modeling, precision oncology
- MeSH terms
- Antineoplastic Agents, Chromosomes, Human, Clinical Trials as Topic, Drug Screening Assays, Antitumor, Encyclopedias as Topic, Humans, Models, Biological, Neoplasms, Pharmacogenetics, Plasma Cells, Genes, ras, Genome, Human, Gene Expression Regulation, Neoplastic, Databases, Factual, Sequence Analysis, DNA, Receptor, IGF Type 1, Receptors, Aryl Hydrocarbon, Cell Lineage, Gene Expression Profiling, Mitogen-Activated Protein Kinase Kinases, Genomics, Cell Line, Tumor, Precision Medicine, Topoisomerase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
